CSIMarket
 


Hutchmed china Limited  (HCM)
Other Ticker:  
 
 

HCM's Revenue Growth by Quarter and Year

Hutchmed China Limited's Revenue results by quarter and year




HCM Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 838.00 426.41 356.13 227.98
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   838.00 426.41 356.13 227.98



HCM Revenue fourth quarter 2023 Y/Y Growth Comment
Hutchmed China Limited showed record Revenue increase in the fourth quarter 2023 with 96.52% from the fourth quarter 2023 2022, to $ 838.00 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue growth. While Hutchmed China Limited' s Revenue jump of 96.52% ranks overall at the positon no. 138 in the fourth quarter 2023.




HCM Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 96.52 % 19.73 % 56.21 % 11.27 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   96.52 % 19.73 % 56.21 % 11.27 %

Financial Statements
Hutchmed China Limited's fourth quarter 2023 Revenue $ 838.00 millions HCM's Income Statement
Hutchmed China Limited's fourth quarter 2022 Revenue $ 426.41 millions Quarterly HCM's Income Statement
New: More HCM's historic Revenue Growth >>


HCM Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   96.52 % 19.73 % 56.21 % 11.27 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #35
Overall #138

Revenue Y/Y Growth Statistics
High Average Low
96.52 % 9.74 % -100 %
(Dec 31 2023)   0
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #35
Overall #138
Revenue Y/Y Growth Statistics
High Average Low
96.52 % 9.74 % -100 %
(Dec 31 2023)   0

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Hutchmed China Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HCM's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


HCM's IV. Quarter Q/Q Revenue Comment


Hutchmed China Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
0
Cumulative Revenue 12 Months Ending $ 838.00 $ 426.41 $ 0.00 $ 356.13 $ 0.00
Y / Y Revenue Growth (TTM) 96.52 % 19.73 % - 56.21 % -
Year on Year Revenue Growth Overall Ranking # 82 # 0 # 0 # 0 # 2013
Seqeuential Revenue Change (TTM) 96.52 % 19.73 % - 56.21 % -
Seq. Revenue Growth (TTM) Overall Ranking # 82 # 0 # 0 # 0 # 3229




Cumulative Revenue growth Comment
With 96.52% annual Revenue growth, Hutchmed China Limited would report a record annual Revenue growth if the fiscal year would end on Dec 31 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 82.

Revenue TTM Q/Q Growth Statistics
High Average Low
96.52 %
28.03 %
-11.23 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 24
Overall # 82

Revenue TTM Y/Y Growth Statistics
High Average Low
96.52 %
28.03 %
-11.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 24
S&P 500 # 82
Cumulative Revenue growth Comment
With 96.52% annual Revenue growth, Hutchmed China Limited would report a record annual Revenue growth if the fiscal year would end on Dec 31 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 82.

Revenue TTM Q/Q Growth Statistics
High Average Low
96.52 %
28.03 %
-11.23 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 24
Overall # 82

Revenue TTM Y/Y Growth Statistics
High Average Low
96.52 %
28.03 %
-11.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 24
S&P 500 # 82




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HCM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for HCM's Competitors
Revenue Growth for Hutchmed China Limited's Suppliers
Revenue Growth for HCM's Customers

You may also want to know
HCM's Annual Growth Rates HCM's Profitability Ratios HCM's Asset Turnover Ratio HCM's Dividend Growth
HCM's Roe HCM's Valuation Ratios HCM's Financial Strength Ratios HCM's Dividend Payout Ratio
HCM's Roa HCM's Inventory Turnover Ratio HCM's Growth Rates HCM's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Lipocine Inc 164.58%$ 164.577 millions
Blueprint Medicines Corporation163.28%$ 163.282 millions
Celldex Therapeutics inc 156.11%$ 156.107 millions
Intelgenx Technologies Corp 141.04%$ 141.040 millions
Co diagnostics Inc 140.48%$ 140.476 millions
Aclaris Therapeutics Inc 126.62%$ 126.622 millions
Globus Medical Inc 124.60%$ 124.604 millions
Sanuwave Health Inc 124.26%$ 124.259 millions
Roivant Sciences Ltd 117.80%$ 117.804 millions
Intelligent Bio Solutions Inc 114.22%$ 114.216 millions
Pacific Biosciences Of California Inc 113.62%$ 113.622 millions
Docgo Inc 112.37%$ 112.366 millions
Ionis Pharmaceuticals Inc112.32%$ 112.319 millions
Encompass Health Corporation109.55%$ 109.546 millions
Xencor Inc106.80%$ 106.798 millions
Volitionrx Limited103.79%$ 103.795 millions
Innovative Eyewear Inc 103.16%$ 103.159 millions
Coherus Biosciences inc 101.81%$ 101.808 millions
Palatin Technologies Inc 98.18%$ 98.176 millions
Hutchmed china Limited96.52%$ 96.525 millions
Immunitybio inc 90.41%$ 90.411 millions
Alimera Sciences Inc 89.98%$ 89.978 millions
Procept Biorobotics Corporation83.65%$ 83.652 millions
Ptc Therapeutics inc 83.41%$ 83.412 millions
Catalyst Pharmaceuticals Inc 81.98%$ 81.984 millions
Enovis Corporation79.22%$ 79.224 millions
Esperion Therapeutics inc 71.38%$ 71.378 millions
Electrocore Inc 71.37%$ 71.367 millions
Cvrx inc70.81%$ 70.805 millions
Elite Pharmaceuticals Inc 68.64%$ 68.637 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com